Development and validation of a PBPK model of gepotidacinin rats to predict exposure in human prostate

Poster presented at the 34th ECCMID congress in Barcelona (May 2024) - Development and validation of a PBPK model of gepotidacinin rats to predict exposure in human prostate

This AB-DIRECT project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853976. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

By continuing your navigation, you accept the deposit of third-party cookies intended to offer you videos, sharing buttons, content uploads from social platforms. Learn more

Cookies settings

×

Functional Cookies

This site uses cookies to ensure its proper functioning and cannot be deactivated from our systems. We do not use them for advertising purposes. If these cookies are blocked, certain parts of the site will not be able to function.

Measure of audience

This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.

Google Analytics

See the official site

Interactive Content

This site uses third-party components, such as NotAllowedScript670b4689cd526ReCAPTCHA, Google NotAllowedScript670b4689cd43cMaps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed

Google Maps
To find out more, click on the link.
See the official site
reCaptcha V2
To find out more, click on the link.
See the official site
reCaptcha V3
To find out more, click on the link.
See the official site

Session

Please login to see yours activities!

Other cookies

Our wepage uses cookies to manage user sessions